RESUMEN
Mesotherapy is a technique by which lower doses of therapeutic agents and bioactive substances are administered by intradermal injections to the skin. Through intradermal injections, mesotherapy can increase the residence time of therapeutic agents in the affected area, thus allowing for the use of lower doses and longer intervals between sessions which may in turn improve the treatment outcome and patient compliance. This systematic review aims to summarize the current literature that evaluates the efficacy of this technique for the treatment of hair loss and provides an overview of the results observed. Of the 416 records identified, 27 articles met the inclusion criteria. To date, mesotherapy using 6 classes of agents and their combinations have been studied; this includes dutasteride, minoxidil, growth factors or autologous suspension, botulinum toxin A, stem cells, and mesh solutions/multivitamins. While several studies report statistically significant improvements in hair growth after treatment, there is currently a lack of standardized regimens. The emergence of adverse effects after mesotherapy has been reported. Further large-scale and controlled clinical trials are warranted to evaluate the utility of mesotherapy for hair loss disorders.
Asunto(s)
Mesoterapia , Humanos , Mesoterapia/efectos adversos , Alopecia/tratamiento farmacológico , Minoxidil/uso terapéutico , Resultado del Tratamiento , Inyecciones IntradérmicasRESUMEN
SOTYKTUTM (deucravacitinib) is a newly approved oral agent for managing moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is a highly selective allosteric tyrosine kinase 2 inhibitor targeting dysregulated cytokine responses in psoriasis patients. Its efficacy was demonstrated in two randomized, placebo- and active comparator-controlled phase 3 trials, where a significantly higher proportion of patients, up to 58.4% (194/332), achieved lessening of symptoms at week 16. The recommended dosing regimen of deucravacitinib is 6 mg once daily. More frequent adverse reactions occurring in the deucravacitinib-treated patients include upper respiratory infection (19.2% [161/840]), increase in blood creatine phosphokinase (2.7% [23/840]), herpes simplex infection (2.0% [17/840]), mouth ulcers (1.9% [16/840]), folliculitis (1.7% [14/840]), and acne (1.4% [12/840]). Continuance of treatment for up to week 52 did not increase the exposure-adjusted rates of adverse reactions. The selectivity and specificity of deucravacitinib treatment may improve its long-term safety profile, compared to other Janus kinase inhibitors.
Asunto(s)
Acné Vulgar , Foliculitis , Psoriasis , Humanos , Adulto , Psoriasis/tratamiento farmacológico , ComprimidosRESUMEN
BACKGROUND: Few studies have reported on the use of cannabinoid products to treat hair loss. AIM: This article aims to reconcile cannabinoids' impact on hair growth. METHOD: A comprehensive and structured search was conducted in PubMed and Google Scholar on June 23, 2022. RESULT: While cannabidiol (CBD), a phytocannabinoid, may cause hair growth, several other phytocannabinoids may lead to hair loss. Additionally, the effect of CBD on hair growth may be concentration-dependent. CBD may cause hair loss at high concentrations (≥10 µM). Therefore, the concentration of CBD needs to be adjusted so that it is optimal for hair growth. One trial found that once-daily application of CBD-rich topical cannabis extract for 6 months increased nonvellus hair count by approximately 93.5% in 35 Caucasian AGA patients: 28 males aged 28-72 years [average 43 years] and 7 females aged 46-76 years [average 61 years]. Each application contained 3-4 mg of CBD. The CBD-rich topical cannabis extract was prepared by ultra-pulverizing Cannabis sativa [hemp] flower into a green chalk-like powder [10.78% CBD and 0.21% tetrahydrocannabinol] and then infusing the powder into a lanolin paste and Emu oil carrier. CONCLUSION: Topical CBD preparations require further studies to establish their safety and efficacy profile. An ideal topical cannabinoid preparation should contain CBD at the right concentration and lack other phytocannabinoid adulterants.
Asunto(s)
Alopecia , Cannabinoides , Femenino , Humanos , Masculino , Alopecia/inducido químicamente , Alopecia/tratamiento farmacológico , Cannabidiol , Cannabinoides/efectos adversos , Cannabis , Cabello , Extractos Vegetales , Polvos , Adulto , Persona de Mediana Edad , Anciano , Ensayos Clínicos como AsuntoRESUMEN
Drug-based treatment of superficial fungal infections, such as onychomycosis, is not the only defense. Sanitization of footwear such as shoes, socks/stockings, and other textiles is integral to the prevention of recurrence and reduction of spread for superficial fungal mycoses. The goal of this review was to examine the available methods of sanitization for footwear and textiles against superficial fungal infections. A systematic literature search of various sanitization devices and methods that could be applied to footwear and textiles using PubMed, Scopus, and MEDLINE was performed. Fifty-four studies were found relevant to the different methodologies, devices, and techniques of sanitization as they pertain to superficial fungal infections of the feet. These included topics of basic sanitization, antifungal and antimicrobial materials, sanitization chemicals and powder, laundering, ultraviolet, ozone, nonthermal plasma, microwave radiation, essential oils, and natural plant extracts. In the management of onychomycosis, it is necessary to think beyond treatment of the nail, as infections enter through the skin. Those prone to onychomycosis should examine their environment, including surfaces, shoes, and socks, and ensure that proper sanitization is implemented.
Asunto(s)
Dermatomicosis , Onicomicosis , Antifúngicos/uso terapéutico , Dermatomicosis/tratamiento farmacológico , Humanos , Onicomicosis/tratamiento farmacológico , Onicomicosis/prevención & control , Zapatos , TextilesRESUMEN
Terbinafine and itraconazole are the most commonly used oral antifungals to treat onychomycosis and superficial dermatomycoses. Recently, poor response to oral terbinafine has been reported. We have summarized the most appropriate dosing regimens of posaconazole, fosravuconazole, voriconazole, and oteseconazole (VT-1161) to treat onychomycosis and superficial fungal infections. A structured search on PubMed and Google Scholar was conducted. Additionally, the bibliographies of selected articles were searched to identify relevant records. The number of records identified from the searches was 463, with 50 articles meeting the inclusion criteria for review. None of the new azoles are US FDA approved for onychomycosis treatment; however, an increasing number of studies have evaluated these agents. The efficacies (complete cure and mycologic cure) of the antifungal agents for dermatophyte great toenail onychomycosis treatment are terbinafine 250 mg/day × 12 weeks (Phase III trial) (38%, 70%), itraconazole 200 mg/day × 12 weeks (Phase III trial) (14%, 54%), posaconazole 200 mg/day × 24 weeks (Phase IIB) (54.1%, 70.3%), fosravuconazole 100 mg/day ravuconazole equivalent × 12 weeks (Phase III) (59.4%, 82.0%), and oteseconazole 300 mg/day loading dose × 2 weeks (Phase II), followed by 300 mg/week × 10 weeks (maintenance dose) (45%, 70%). Guidelines for monitoring are also presented.
Asunto(s)
Terapias Complementarias , Fármacos Dermatológicos , Dermatosis del Pie , Onicomicosis , Humanos , Onicomicosis/tratamiento farmacológico , Antifúngicos/uso terapéutico , Terbinafina/uso terapéutico , Itraconazol/uso terapéutico , Voriconazol/uso terapéutico , Dermatosis del Pie/tratamiento farmacológico , Naftalenos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Resultado del TratamientoRESUMEN
Low-level laser therapy (LLLT) is used to treat androgenetic alopecia (AGA). The therapeutic effect of LLLT on AGA has been evaluated; however, there is a paucity of studies that investigated device- and usage-related factors that may influence the effect of LLLT on hair regrowth. The literature was systematically searched to identify eligible studies; PubMed, Scopus, EMBASE and clinicaltrials.gov databases were searched on 30 April 2020. Eligible studies were randomized trials that investigated the effect of LLLT on hair density in AGA. Robust linear regressions were used to make comparisons. An increase in the per-session energy fluence by 1 J/cm2 is significantly associated with an increase in hair density by 0.23 hairs/cm2 (95% CI: 0.21 hairs/cm2 , 0.25 hairs/cm2 ). The number of laser or light-emitting diodes is not significantly associated with change in hair density. Increasing the total duration of exposure to treatment is associated with a significant increase in hair density (ß = .53, P < .05). Switching from continuous to pulse irradiation was associated with a significant increase in hair density (ß = 10.11, P < .01). Energy fluence, irradiation session duration, and light pulsing have a significant therapeutic effect on AGA, while the number of diodes does not.
Asunto(s)
Alopecia , Terapia por Luz de Baja Intensidad , Alopecia/diagnóstico , Alopecia/radioterapia , Cabello , Humanos , Luz , Resultado del TratamientoRESUMEN
Nail plate brittleness (or fragility) is a common complaint affecting up to 20% of the population, especially women over 50 years of age, with fingernail fragility being more prevalent than toenail fragility. Nail brittleness is characterized by nails that split, flake and crumble, become soft and lose elasticity. The main clinical presentations are: onychoschizia, onychorrhexis, superficial granulation of keratin and worn-down nails. According to causative factors, we can distinguish 2 forms of nail fragility (NF): a primary "idiopathic or brittle nail syndrome" form and NF secondary to different causes such as inflammatory nail disorders, infections, systemic diseases and general conditions, traumas and alteration of the nail hydration. Optimal management requires treatment of the primary cause of brittle nails, when possible. In idiopathic NF oral supplementation, vitamins (especially biotin, also known as vitamin B7), trace elements and amino acids (especially cysteine) have been reported to be useful. In addition, several products, such as topical moisturizers and lacquers could be considered to restructure the affected nail plate and to reduce psychological impacts of this common problem.
RESUMEN
BACKGROUND: Platelet-rich plasma (PRP) treatment may encourage hair growth by promoting cellular maturation, differentiation, and proliferation. OBJECTIVE: The objective of this study was to evaluate the effectiveness of PRP as a treatment for androgenetic alopecia (AGA). MATERIALS AND METHODS: A literature search combined with meta-analysis was used to calculate the overall standardized mean difference (SMD) in hair density in patients treated with PRP injections in comparison with baseline and placebo treatment. Chi squared analysis and Fisher exact test were used to investigate variation in protocols. RESULTS: The overall SMD in hair density was 0.58 (95% confidence interval [CI]: 0.35-0.80) and 0.51 (95% CI: 0.23-0.80, p < .0004) in favor of PRP treatment when compared with baseline and placebo treatment, respectively. CONCLUSION: Platelet-rich plasma is beneficial in the treatment of AGA. It is recommended that 3 monthly sessions of PRP (once monthly ×3 treatments) be used followed by a 3- to 6-month maintenance period.
Asunto(s)
Alopecia/terapia , Transfusión de Sangre Autóloga/métodos , Plasma Rico en Plaquetas , Diferenciación Celular , Proliferación Celular , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Cabello/fisiología , Humanos , Inyecciones Subcutáneas , Masculino , Resultado del TratamientoRESUMEN
Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, topical monotherapies for treatment of AGA in men. A literature search was conducted to obtain randomized, controlled and blinded studies that investigated off-label, topical, monotherapies in male patients. Hair density, hair diameter and hair growth were used to evaluate treatment success. Fourteen off-label topical therapies were investigated among the 16 studies that met inclusion criteria. Nine off-label therapies were reported to produce a significantly greater improvement in hair restoration parameters (e.g. mean change from hair count and hair diameter) as compared to placebo (p < 0.05 for all treatments). In two studies, procyanidin oligomers exhibited greater efficacy over vehicle with response to mean change in hair density (hairs/cm2) (ps < 0.0001 at Week 24). In conclusion, prostaglandin analogs and polyphenols, such as latanoprost and procyanidin oligomers, can improve hair restoration parameters in male AGA patients, possibly through targeting mechanisms proposed in the etiology of AGA. The current evidence suggests short-term (24 weeks) use may provide benefit for hair loss patients; however, long-term efficacy and safety data are required.
Asunto(s)
Alopecia/tratamiento farmacológico , Cabello/crecimiento & desarrollo , Uso Fuera de lo Indicado , Administración Tópica , Adulto , Biflavonoides/administración & dosificación , Catequina/administración & dosificación , Humanos , Latanoprost/administración & dosificación , Proantocianidinas/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del TratamientoRESUMEN
Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophyte molds, and yeasts. This difficult-to-treat chronic infection has a tendency to relapse despite treatment. This paper aims to offer a global perspective on onychomycosis management from expert physicians from around the world. Overall, the majority of experts surveyed used systemic, topical, and combination treatments approved in their countries and monitored patients based on the product insert or government recommendations. Although the basics of treating onychomycosis were similar between countries, slight differences in onychomycosis management between countries were found. These differences were mainly due to different approaches to adjunctive therapy, rating the severity of disease and use of prophylaxis treatment. A global perspective on the treatment of onychomycosis provides a framework of success for the committed clinician with appreciation of how onychomycosis is managed worldwide.
Asunto(s)
Antifúngicos/uso terapéutico , Dermatosis del Pie/terapia , Salud Global , Onicomicosis/terapia , Administración Oral , Administración Tópica , Antifúngicos/farmacología , Arthrodermataceae/aislamiento & purificación , Arthrodermataceae/patogenicidad , Ensayos Clínicos como Asunto , Comorbilidad , Interacciones Farmacológicas , Dermatosis del Pie/epidemiología , Dermatosis del Pie/microbiología , Carga Global de Enfermedades , Humanos , Terapia por Luz de Baja Intensidad/métodos , Onicomicosis/epidemiología , Onicomicosis/microbiología , Fotoquimioterapia/métodos , Prevalencia , Recurrencia , Tiña del Pie/tratamiento farmacológico , Tiña del Pie/epidemiología , Resultado del Tratamiento , Levaduras/aislamiento & purificación , Levaduras/patogenicidadRESUMEN
Onychomycosis is a fungal infection of the nail primarily caused by the dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes. The topical-based treatment of onychomycosis remains a challenge because of the difficulty associated with penetrating the dense, protective structure of the keratinized nail plate. Tavaborole is a novel small-molecule antifungal agent recently approved in the United States for the topical treatment of toenail onychomycosis. The low molecular weight, slight water solubility, and boron chemistry of tavaborole maximize nail penetration after topical application, allowing for effective targeting of the infection in the nail bed. The efficacy of tavaborole is associated with its novel mechanism of action, whereby it inhibits the fungal leucyl-tRNA synthetase (LeuRS) enzyme. Because LeuRS is an essential component in fungal protein synthesis, inhibition of LeuRS ultimately leads to fungal cell death. Tavaborole is the first boron-based antifungal medication approved for the treatment of mild-to-moderate onychomycosis and presents patients with a new topical option. Previously, ciclopirox and efinaconazole were the only approved topical treatments for onychomycosis. This article details the properties that are at the core of the clinical benefits associated with tavaborole.
Asunto(s)
Compuestos de Boro/farmacocinética , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacocinética , Onicomicosis/tratamiento farmacológico , Humanos , Pruebas de Sensibilidad Microbiana , Uñas/efectos de los fármacos , Uñas/microbiología , Onicomicosis/metabolismo , Resultado del TratamientoRESUMEN
BACKGROUND: Low-level laser therapy (LLLT) is currently in use to stimulate hair growth and is quickly gaining in popularity due to the ease of use and absence of side effects. In 2015 alone, the number of LLLT devices with the Food and Drug Administration clearance has doubled. OBJECTIVE: To consolidate evidence and establish which data are still required for the widespread acceptance of LLLT for hair loss therapy. METHODS AND MATERIALS: A thorough search of the PubMed database was conducted to obtain studies investigating LLLT for androgenetic alopecia in men and women. RESULTS: Nine trials were identified for comb and helmet/cap devices, five of which were randomized controlled trials. Data comparison across LLLT trials and with traditional hair loss therapy (minoxidil, finasteride) was not straight forward because there was a lack of visual evidence, sample sizes were low, and there were large variations in study duration and efficacy measurements. CONCLUSION: There are a number of unanswered questions about the optimum treatment regimen, including maintenance treatment and the long-term consequences of LLLT use. Moving forward, protocols should be standardized across trials. Moreover, it is recommended that future trials include visual evidence and trial duration be expanded to 12 months.
Asunto(s)
Alopecia/radioterapia , Medicina Basada en la Evidencia , Terapia por Luz de Baja Intensidad , Humanos , Terapia por Luz de Baja Intensidad/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del TratamientoRESUMEN
BACKGROUND: Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent. Three broad categories of agents are used to treat SD: antifungal agents, keratolytics, and corticosteroids. Topical therapies are the first line of defense in treating this condition. OBJECTIVE: Our objective was to critically review the published literature on topical treatments for facial SD. METHODS: We searched PubMed, Scopus, Clinicaltrials.gov, MEDLINE, Embase, and Cochrane library databases for original clinical studies evaluating topical treatments for SD. We then conducted both a critical analysis of the selected studies by grading the evidence and a qualitative comparison of results among and within studies. RESULTS: A total of 32 studies were eligible for inclusion, encompassing 18 topical treatments for facial SD. Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment. CONCLUSION: Promiseb®, desonide, mometasone furoate, and pimecrolimus were found to be effective topical treatments for facial SD, as they had the lowest recurrence rate, highest clearance rate, and the lowest severity scores (e.g., erythema, scaling, and pruritus), respectively. Ciclopirox olamine, ketoconazole, lithium (gluconate and succinate), and tacrolimus are also strongly recommended (level A recommendations) topical treatments for facial SD, as they are consistently effective across high-quality trials (randomized controlled trials).
Asunto(s)
Antiinflamatorios/uso terapéutico , Antifúngicos/uso terapéutico , Dermatitis Seborreica/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Dermatosis Facial/tratamiento farmacológico , Administración Cutánea , Antiinflamatorios/efectos adversos , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Inhibidores de la Calcineurina/administración & dosificación , Inhibidores de la Calcineurina/efectos adversos , Inhibidores de la Calcineurina/uso terapéutico , Ciclopirox , Dermatitis Seborreica/microbiología , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Desonida/administración & dosificación , Desonida/efectos adversos , Desonida/uso terapéutico , Dermatosis Facial/microbiología , Humanos , Cetoconazol/administración & dosificación , Cetoconazol/efectos adversos , Cetoconazol/uso terapéutico , Malassezia/efectos de los fármacos , Furoato de Mometasona/administración & dosificación , Furoato de Mometasona/efectos adversos , Furoato de Mometasona/uso terapéutico , Preparaciones de Plantas/administración & dosificación , Preparaciones de Plantas/efectos adversos , Preparaciones de Plantas/uso terapéutico , Guías de Práctica Clínica como Asunto , Piridonas/administración & dosificación , Piridonas/efectos adversos , Piridonas/uso terapéutico , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Tacrolimus/administración & dosificación , Tacrolimus/efectos adversos , Tacrolimus/análogos & derivados , Tacrolimus/uso terapéutico , Resultado del Tratamiento , Vitaminas/administración & dosificación , Vitaminas/efectos adversos , Vitaminas/uso terapéuticoRESUMEN
BACKGROUND: Onychomycosis is a difficult-to-treat infection whose current treatment paradigm relies primarily on oral antifungals. The emergence of new topical drugs broadens the therapeutic options and prompts a re-evaluation of the current Canadian treatment strategy. OBJECTIVE: To define a patient-centred Canadian treatment strategy for onychomycosis. METHODS: An expert panel of doctors who treat onychomycosis was convened. A systematic review of the literature on treatments for onychomycosis was conducted. Based on the results, a survey was designed to determine a consensus treatment system. RESULTS: First-line therapy should be selected based on nail plate involvement, with terbinafine for severe onychomycosis (>60% involvement), terbinafine or efinaconazole for moderate onychomycosis (20%-60% involvement), and efinaconazole for mild onychomycosis (<20% involvement). Comorbidities, patient preference and adherence, or nail thickness may result in the use of alternative oral or topical antifungals. CONCLUSION: These guidelines allow healthcare providers and patients to make informed choices about preventing and treating onychomycosis.
Asunto(s)
Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Onicomicosis/tratamiento farmacológico , Canadá , Consenso , Vías Clínicas , Humanos , Uñas/microbiología , Guías de Práctica Clínica como Asunto , Dedos del Pie/microbiologíaRESUMEN
External genital warts (EGWs) resulting from the human papilloma virus (HPV) are a common sexually transmitted infection and cause significant impairments in patient quality of life and sexual well-being. Therapeutic options for EGWs can be provider-assisted, but many patients opt for treatment that can be applied at home. Sinecatechins 10% ointment is a new botanically based patient-administered therapy for EGWs. It is comprised of >85% catechins, green tea polyphenols that have been shown to possess antioxidant, antiproliferative, antiviral, and antitumor properties. Phase III trials of sinecatechins 10% ointment have demonstrated higher efficacy and lower recurrence rates compared to currently available patient-applied treatments. Therefore, sinecatechins 10% ointment presents an alternative self-administered topical treatment for EGWs.
Asunto(s)
Catequina/administración & dosificación , Condiloma Acuminado/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Administración Tópica , Catequina/farmacología , Condiloma Acuminado/virología , Humanos , Pomadas , Infecciones por Papillomavirus/tratamiento farmacológico , Infecciones por Papillomavirus/virología , Extractos Vegetales/farmacología , Polifenoles/administración & dosificación , Polifenoles/farmacología , Calidad de Vida , Recurrencia , Autoadministración , Té/químicaRESUMEN
INTRODUCTION: Onychomycosis is an infection of the nail plate that is an important priority area for the development of antifungal drugs. The high incidence of relapse and reinfection often makes onychomycosis a chronic condition. The current gold standard is oral therapy, but the development of effective topical agents remains a priority as they have fewer systemic interactions. AREAS COVERED: This review summarizes development of antifungals from early phase development through Phase III clinical trials for onychomycosis. The oral molecules in development are azole molecules. Topical drugs in development include azoles, allylamines, benzoxaboroles and nanoemulsions. Photosensitizers for photodynamic therapy and new laser systems are also emerging therapeutic options. There is a diverse array of antifungal drugs in the early phases of development. EXPERT OPINION: The goals of onychomycosis therapy are a mycological cure and a normal appearing nail. The recent development of topical antifungals has been successful at improving the nail permeation and efficacy. The diversification of molecular targets is the next primary goal of antifungal development. Incomplete treatment of onychomycosis provides an environment conducive to the development of antifungal resistance. New topical agents and device-based therapies expand the therapeutic options. Combination therapy using multiple drug classes may improve the overall efficacy of antifungal treatment in onychomycosis.
Asunto(s)
Antifúngicos/uso terapéutico , Onicomicosis/tratamiento farmacológico , Administración Oral , Administración Tópica , Animales , Ensayos Clínicos como Asunto , Humanos , Terapia por Luz de Baja Intensidad , Onicomicosis/radioterapia , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéuticoRESUMEN
Cosmetic improvement in nail appearance is a great concern to patients with onychomycosis. Although oral and topical treatments for onychomycosis can potentially eradicate the infection, unsightly nails may remain despite negative mycology. Laser-based devices have been approved for the temporary clearance of nails with onychomycosis, thus providing a means of improving the aesthetic appearance of the nails. A retrospective chart review of patients treated with a Nd:YAG 1064-nm laser and debridement for onychomycosis, and terbinafine 1% cream for associated tinea pedis, between July 2012 and February 2014 was performed to ascertain the proportion of patients who achieved clinical outcomes. A temporary improvement in the appearance of the target nail was observed in 78% of patients and the affected area of the nail plate was reduced by at least 50% from baseline in 46% of patients. It appears that patients whose great toenails are potentially infected with non-dermatophyte molds may particularly benefit from laser therapy. Higher clinical outcome rates were observed with administration of four or more treatments, but additional observations and/or studies are needed to optimize the regimen of laser therapy to improve the cosmetic appearance of infected nails.
Asunto(s)
Dermatosis del Pie/terapia , Láseres de Estado Sólido/uso terapéutico , Onicomicosis/terapia , Administración Tópica , Adulto , Desbridamiento , Femenino , Humanos , Terapia por Luz de Baja Intensidad/métodos , Masculino , Persona de Mediana Edad , Naftalenos/administración & dosificación , Estudios Retrospectivos , Terbinafina , Resultado del TratamientoRESUMEN
Systemic antifungal treatments are believed to be more effective than topicals for the treatment of onychomycosis; however, they are associated with more risks of adverse events. Tavaborole is the first member of a new class of antifungals that has been developed as a new topical nail solution for the treatment of toenail onychomycosis caused by dermatophytes. During Phase I-III clinical trials, tavaborole 5.0% nail solution showed a favorable safety and efficacy profile. Tavaborole 5.0% received US FDA market approval on 8 July 2014.
Asunto(s)
Antifúngicos/uso terapéutico , Compuestos de Boro/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Dermatosis del Pie/tratamiento farmacológico , Onicomicosis/tratamiento farmacológico , Antifúngicos/química , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Compuestos de Boro/química , Compuestos de Boro/farmacocinética , Compuestos de Boro/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/química , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacocinética , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Evaluación de Medicamentos , Humanos , Pruebas de Sensibilidad MicrobianaRESUMEN
Androgenetic alopecia (AGA) is a persistent and pervasive condition that affects men worldwide. Some common treatment options for AGA include hair prosthetics, oral and topical medications, and surgical hair restoration (SHR). Pharmaceutical and SHR treatments are associated with limitations including adverse side effects and significant financial burden. Low-level laser or light (LLL) devices offer alternative treatment options that are not typically associated with adverse side effects or significant costs. There are clinic- and home-based LLL devices. One home-based laser comb device has set a standard for others; however, this device requires time devoted to carefully moving the comb through the hair to allow laser penetration to the scalp. A novel helmet-like LLL device for hair growth has proven effective in preliminary trials and allows for hands-free use. Regardless, there are few clinical trials that have been conducted regarding LLL devices for AGA and results are mixed. Further research is required to establish the true efficacy of these devices for hair growth in comparison to existing alternative therapies.
Asunto(s)
Alopecia/radioterapia , Terapia por Luz de Baja Intensidad/métodos , Alopecia/epidemiología , Alopecia/patología , Diseño de Equipo , Humanos , Terapia por Luz de Baja Intensidad/instrumentación , Masculino , Resultado del TratamientoRESUMEN
Efinaconazole 10% nail solution (Jublia(®)) is a new topical triazole antifungal designed for the topical treatment of distal and lateral subungual onychomycosis. It inhibits ergosterol biosynthesis enzyme sterol 14α-demethylase. Efinaconazole has lower minimum inhibitory concentrations than terbinafine, ciclopirox, itraconazole and amorolfine in Trichophyton rubrum, Trichophyton mentagrophytes and Candida albicans. The solution based formula has low surface tension and keratin binding properties that increase penetrance through the nail plate. Safety studies have shown that this formulation is not associated with atopic dermatitis or contact sensitivity. Duplicate Phase III clinical trials in adults with mild to moderate distal and lateral subungual onychomycosis indicate that efinaconazole 10% solution is an effective therapy with a pooled complete cure rate of 17% and a pooled mycological cure rate of 54%. Efinaconazole 10% nail solution is a safe and effective new topical therapy for onychomycosis, which will fill a pressing need for more effective topical therapy in this disease.